Dr. Michael B. Brumback, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 539
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Emory University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME 84983
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Ascension St Vincent's Riverside Jacksonville, FL
- Ascension St Vincent's Southside Jacksonville, FL
- Southeast Georgia Health System -- Camden Campus Saint Marys, GA
- Ed Fraser Memorial Hospital Macclenny, FL
Medical groups
- James D Baker III MD PA (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 539
- Services billed
- 2,232
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 462 | 225 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 436 | 151 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 230 | 114 |
| Established patient office or other outpatient visit, 40-54 minutes | 215 | 91 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 165 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 101 | 97 |
| New patient office or other outpatient visit, 45-59 minutes | 48 | 48 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 27 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Nifedipine Er (nifedipine) Other prescribers in Jacksonville, FL | 234 |
| Carvedilol Other prescribers in Jacksonville, FL | 181 |
| Losartan Potassium Other prescribers in Jacksonville, FL | 164 |
| Amlodipine Besylate Other prescribers in Jacksonville, FL | 110 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Jacksonville, FL | 105 |
| Furosemide Other prescribers in Jacksonville, FL | 94 |
| Calcitriol Other prescribers in Jacksonville, FL | 93 |
| Prednisone Other prescribers in Jacksonville, FL | 57 |
| Atorvastatin Calcium Other prescribers in Jacksonville, FL | 55 |
| Valsartan Other prescribers in Jacksonville, FL | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 83 payments worth $1,932 in total to this clinician.
| Amgen Inc. | $325 |
|---|---|
| Otsuka America Pharmaceutical, Inc. | $210 |
| Novartis Pharmaceuticals Corporation | $184 |
| Calliditas Therapeutics US Inc. | $158 |
| Akebia Therapeutics Inc | $141 |
| Bayer HealthCare Pharmaceuticals Inc. | $124 |
| Fresenius USA Marketing, Inc. | $111 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $109 |
| Food and Beverage | $1,884 |
|---|---|
| Education | $47.66 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Opko Pharmaceuticals, LLC Feb 17, 2025 | Education RAYALDEE · NEPHROLOGY · in-kind | $23.25 |
| Opko Pharmaceuticals, LLC Mar 25, 2025 | Education RAYALDEE · NEPHROLOGY · in-kind | $21.64 |
| Travere Therapeutics, Inc. Apr 29, 2025 | Education Filspari · Kidney Disease · in-kind | $2.38 |
| Travere Therapeutics, Inc. Dec 15, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.